Filing Details

Accession Number:
0001567619-21-013567
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-07-16 16:02:21
Reporting Period:
2021-07-14
Accepted Time:
2021-07-16 16:02:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1559053 Prothena Corp Public Ltd Co PRTA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1242880 S Christopher Henney C/O Prothena Biosciences Inc
331 Oyster Point Boulevard
South San Francisco CA 94080
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares, Par Value $0.01 Per Share Acquisiton 2021-07-14 11,108 $11.33 11,108 No 4 M Direct
Ordinary Shares, Par Value $0.01 Per Share Disposition 2021-07-14 9,108 $55.31 2,000 No 4 S Direct
Ordinary Shares, Par Value $0.01 Per Share Disposition 2021-07-14 2,000 $56.13 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Stock Option (Right to Buy) Disposition 2021-07-14 11,108 $0.00 11,108 $11.33
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2030-05-20 No 4 M Direct
Footnotes
  1. The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. The transaction was executed in multiple trades in prices ranging from $55.00 to $55.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. The transaction was executed in multiple trades in prices ranging from $56.005 to $56.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  4. The shares subject to the option were fully vested as of the date of the exercise.